Introduction
Equine arteritis virus (EAV) is a member of a group of small positive-stranded RNA viruses that also includes lactate dehydrogenase-elevating virus (LDV), simian haemorrhagic fever virus and porcine respiratory and reproductive syndrome virus (Plagemann & Moennig, 1992) . EAV was originally classified as a togavirus based on its isometric nucleocapsid morphology, small virion size (45 to 70 nm) and the length of its RNA genome (12.7 kb) (Porterfield et al., 1978) . More recent studies demonstrated that the genomic organization and replication strategy of this group of Viruses closely resemble those of the coronavirus family (van Berlo et al., 1982 Vries et al., 1990; den Boon et al., 1991 ; Kuo et al., 1991 ; Conzelmann et al., 1993; Godeny et al., 1993; Meulenberg et al., 1993) .
Four structural proteins have been identified and assigned to open reading frames (ORFs) within the EAV genome (de Vries et al., 1992) . These are a 14 kDa nucleocapsid protein (N; ORF 7), a 16kDa nonglycosylated membrane protein (M; ORF 6) and two Nglycosylated membrane proteins of 25 kDa and 30-42 kDa (G s and GL; ORFs 2 and 5, respectively). Neutralizing monoclonal antibodies (MAbs) have been identified which recognize a single site or overlapping sites on the G L protein (Balasuriya et al., 1993 (Balasuriya et al., , 1995 Deregt et al., 1994) .
Only one serotype of EAV has been recognized so far (Fukunaga & McCollum, 1977) , but differences among EAV isolates have been demonstrated biologically, antigenically and by sequence comparisons. The Bucyrus isolate of EAV will reproducibly cause a moderate to severe clinical illness in experimentally exposed horses, characterized by pyrexia, conjunctivitis, rhinitis, depression, limb and palpebral oedema and anorexia (Bryans et Timoney & McCollum, 1993) . Minor antigenic differences among isolates have been detected using polyclonal antiserum (Fukunaga & McCollum, 1977) and oligonucleotide fingerprint comparisons of genomic RNAs from geographically diverse isolates suggest that sequence differences may exceed 5% (Murphy et al., 1992) . Direct comparison of the nucleotide sequences from the M and N genes of diverse isolates revealed differences of 3 % to 7 % within these two ORFs (Chirnside et al., 1994) . However, correlation of antigenic differences with sequence differences or with biological phenotype has been hampered by the lack of more specific reagents. We have characterized three EAV-specific neutralizing MAbs and have demonstrated that these antibodies recognize a related amino acid sequence within the G L protein. We have used these antibodies to compare 19 independent field isolates of EAV by virus neutralization (VN) to our Bucyrus isolate of EAV (EAV-NVSL) and to the non-pathogenic vaccine virus (ARVAC; Doll et al., 1968; McCollum, 1969 McCollum, , 1986 . We have also compared the nucleotide and deduced amino acid sequence of ORF 5 from a naturally neutralization-resistant (NR) virus (DLll) and MAb NR escape mutants derived from EAV-NVSL with those of wild-type EAV-NVSL, the vaccine virus, an additional independent virus isolate which is neutralized by the MAbs (DL8), and with the previously published Bucyrus sequence (den Boon et al., 1991).
Methods

Cells and viruses. Simian virus 40-transformed primary equine ovary (EO) cells (R.
A. Donis, University of Nebraska, USA, unpublished data) were maintained in MEM with Earle's salts (MEM-E; Gibco), 15% Nu-Serum (Collaborative Biomedical Products), 200IU/ml penicillin and 200 IU/ml streptomycin at 37 °C in 5% CO s. RK-13 cells were maintained in MEM-E, 10% fetal bovine serum (FBS), 200 IU/ml penicillin and 200 IU/ml streptomycin. SP2/0-Ag.14 myeloma cells (Tovey & Lenoir, 1978) were maintained in Dulbecco's modified Eagle's medium (Gibco) with 4.5 mg/ml glucose, 20% FBS, 200 IU/ml penicillin and 200 IU/ml streptomycin at 37 °C in 5 % CO s. EAV-NVSL was obtained from the National Veterinary Services Laboratory (NVSL; Ames, Iowa, USA) and propagated in EO cells. Cells were infected with 0.01 TCIDs0 units of virus per cell. The culture supernatant was collected when > 90 % of the cells showed c.p.e. Virus was pelleted by ultracentrifugation at 80000g for 1 h at 4°C, resuspended in PBS and purified on a potassium tartrate-glycerol step gradient (Obijeski et al., 1974) . The position of the virus band was initially determined by assaying fractions in a TCIDs0 assay on EO cells. Virus harvested from the gradient was diluted in PBS, pelleted by ultracentrifugation, resuspended in PBS and stored at -70 °C. EAV isolates, obtained from acutely or persistently infected animals, were amplified in EO cells, aliquoted and stored at -70 °C. Titres were determined by TCIDs0 assays using EO ceils. Passage histories and origins of these isolates are indicated in Table 1 .
MAbs. Virus was denatured using 0.06% formalin for 5 h at 37 °C (Harty & Plagemann, 1988) . BALB/c mice were inoculated subcutaneously with 109 TCID~0 units of virus in Freund's complete adjuvant. Booster inoculations were administered intraperitoneally at 3 and 6 weeks using Freund's incomplete adjuvant, followed by a final boost of native virus without adjuvant 8 weeks after primary immunization. Spleen cells were fused with SP2/0-Ag. 14 myeloma cells and plated into 10 96-well plates. All wells were screened by indirect immunofluorescence (IF) on slides containing EAV-NVSL-infected EO cells and by VN assays carried out on the same cell line. Antibody specificity for viral proteins was confirmed by IF screening on mockinfected EO ceils.
Neutralizing activity against 100 TCIDs0 units of virus was determined by lack of c.p.e, at 48 h. Hybridomas positive by IF or VN were cloned twice by limiting dilution. Antibody isotypes were identified with an ELISA-based kit (Zymed). Ascites fluids were produced using BALB/c mice (Harlow & Lane, 1988) and stored at -20 °C.
Determination of VN titres. Twofold serial dilutions of ascites fluid were made in 96-well microtitre plates and 100 TCIDs0 units of virus were added per well. The plates were then incubated at room temperature for 1 h after which approximately l0 s RK-13 cells were added. Plates were maintained at 37 °C in 5 % CO 2. Plates were read when wells containing 100 TCIDs0 units of virus but no antibody showed complete c.p.e. (48 to 96 h). Results of duplicate tests are expressed as the reciprocal of the dilution which resulted in the protection of 75 % of the cells when compared to wells without antibody.
Generation of NR mutants.
A non-plaque-purified stock of EAV-NVSL was passaged twice in the presence of 10 % ascites fluid from MAb 93B, 74D(B) or 38F. NR virus variants were obtained from the pool of progeny virus by two rounds of plaque purification. NR phenotypes were confirmed in a VN assay as detailed above.
Metabolic' labelling of cells. Newly confluent monolayers of EO cells were infected with EAV-NVSL at a m.o.i, of > 10 TCIDs0 units per cell. At 7.5 h post-infection (p.i.), the monolayers were rinsed with PBS and overlaid with medium deficient in methionine. At 8 h p.i. cells were overlaid with methionine-free medium containing 100 ~tCi/ml Tran 3~S-label (> 1000 Ci per mmol; ICN) and incubated for 4 h. After the appropriate labelling time was complete, the cells were rinsed twice with ice-cold PBS and lysed in 200 gl lysis buffer (100 mM-NaCI, 50 mM-Tris-HC1 pH 8.0, 5 mM-EDTA, 1% Triton X-100, 50 ~tM-PMSF and 50 gg/ml aprotinin). Insoluble material was pelleted at 13000 r.p.m, in a microfuge and supernatants were stored at -70 °C. When performing a pulse-chase experiment, cells were labelled for 15 min, rinsed twice with medium containing excess methionine and lysed immediately or further incubated in chase medium for 15, 30, 60, 90 or 120 min before cell disruption. To analyse simultaneously intraand extracellular proteins, total lysates were prepared by addition of 0.25 volume of 5 x lysis buffer with 100 mM-NaC1 directly to the chase medium.
To prepare radiolabelled virions, EAV-NVSL-infected cells were incubated with Tran aSS-label for 5 h after which 0.1 volumes of complete medium were added to the cells. Supernatant was collected when > 80 % of the cells showed c.p.e. (approximately 24 h p.i.). Cellular debris was removed by centrifugation in a microfuge at 13 000 r.p.m for 5 min. Virus particles were pelleted by ultracentrifugation as described above, resuspended in lysis buffer and stored at -70 °C.
Immunoprecipitation and gel electrophoresis. Cytoplasmic lysates (CL) or detergent-disrupted virions (VL) were diluted five-to 10-fold in TNE-RIP buffer (200 mM-NaC1, 50 mM-Tri~HCI pH 8.0, 5 mM- EDTA, 1% Triton X-100, 1% deoxycholic acid and 0.1% SDS) and either 2 gl of ascites fluid or 100 gl of hybridoma culture supernatant were added. Immunoprecipitations with anti-peptide sera specific for N, M, G~ and G s were done as described (de Vries et al., 1992; Deregt et al., 1994) . Samples were incubated at 4 °C overnight, after which 30 gl of a 50 % suspension of recombinant protein G-Sepharose 4B (Zymed) was added to the tubes. Samples were incubated at room temperature for 2 h with frequent agitation and immune complexes were collected by centrifngation and rinsed three times with TNE-RIP buffer. Pellets were resuspended in 20 gl sample buffer containing 100 mM-DTT (Laemmli, 1970) , heated at 60 °C for 1 min and loaded onto discontinuous SDS-12% polyacrylamide gels (Sambrook et al., 1989) .
Western blotting. Ten gl each of CL from mock-infected cells, CL fiom EAV-NVSL-infected cells lysed at 10 h p.i. or VL were separated by SDS-PAGE as described above. Proteins were transferred to nitrocellulose in a semi-dry blotting apparatus at 0.6 V/cm ~ for 1 h (Sambrook et al., 1989) . The primary antibody was tissue culture supernatant from the 93B hybridoma diluted 1:100. Blots were developed using an Immun-Lite II kit (Bio Rad).
Fluorography. Gels were fixed in methanol-acetic acid (Sambrook et al., 1989) , impregnated with 2,5-diphenyloxazole (Bonner & Laskey, 1974) , dried on Fisher 3MM filter paper and exposed to Kodak SB film at -70 °C.
RT-PCR amplification and sequence analysis. Virus RNA was extracted from pelleted virions using acid guanidinium thiocyanatephenol-chloroform (Chomczynski & Sacchi, 1987) . Five gg of viral RNA was reverse-transcribed in a 20 ~1 reaction mixture containing 250ng random DNA oligonucleotide fragments, 10mM-dNTPs, 20 mM-DTT, 50 mM-Tris HC1 pH 8"3, 50 mM-KC1, 2.5 mM-spermidine and 7 units of avian myeloblastosis virus reverse transcriptase (Promega) for 1 h at42 °C. Two ~tl ofcDNA was transferred to a 100 lal PCR reaction containing sense and antisense primers, 0.2 mM-dNTPs, 5 mM-KC1, 10 mN-Tris-HC1 pH 8.0, 1 mM-MgC12 and 2.5 units of AmpliTaq DNA polymerase (Perkin Elmer). Amplification was performed under the following conditions: 20 s at 92 °C, 1 min at 42 °C and 1 mi~ at 72 °C with a 1 s extension per cycle for 25 cycles. PCR products were sequenced using [~-a~S]dATP (> 1000Ci/mmol; Amersham) and a PCR product dideoxynucleotide chain termination sequencing kit (United States Biochemical). Sequences were obtained from at least two independent PCR amplifications and from either one or both cDNA strands using the PCR primers and internal primers. Sequence data was assembled and comparisons of EAV sequences were done using the Pileup and Pretty programs of the University of Wisconsin Genetics Computer Group (Devereux et al., 1984) .
Amplification and sequencing primers. Primers were synthesized at the Biotechnology Facility at Cornell University (N.Y., USA). Primers were designed using the published EAV sequence (den Boon et al., 1991) 
Results
Identification of neutralizing antibodies
Three hybridoma clones were identified that secreted antibody which neutralized the infectivity of EAV in a VN test. VN titres on RK-13 cells using EAV-NVSL as * Antibody titres are expressed as the reciprocal of the highest dilution at which 75 % of the cells were protected from c.p.e, compared to wells containing virus but no antibody.
t Plaque-purified.
the indicator virus were > 5120 for all three MAbs ( Table 2 ). The MAbs recognized EAV-NVSL-but not mock-infected EO cells by IF, which suggests that they are directed against viral antigen(s) (data not shown).
Immunoglobulin isotyping revealed that MAbs 93B and 74D(B) are of the IgG2a subclass while MAb 38F is an IgG2b isotype.
The M A b s recognize the G L protein
The protein specificity of the MAbs was determined by immunoprecipitation of [35S]methionine-labelled proteins from CL of mock-or EAV-NVSL-infected EO cells. For comparison, the CLs were incubated with rabbit anti-peptide sera directed against the N, M, G z and G s protein (de Vries et al., 1992; Deregt et al., 1994) . The N-specific anti-peptide serum recognized a single protein of 14 kDa in the CL of EAV-infected cells, while the anti-peptide serum directed against G s specifically immunoprecipitated a 25 kDa protein from the CL of cells infected with EAV. The M-and G~-specific antipeptide sera each precipitated three virus proteins with On the basis of its size and its relatively efficient immunoprecipitation by the M-specific anti-peptide serum, the 16kDa product was identified as the unglycosylated M protein. The 27 and 30 kDa products therefore most probably represent different forms of the heterogeneously N-glycosylated GL protein (de Vries et al., 1992) . After incubation of the CL from EAV-infected cells with the MAbs, three proteins were again precipitated which co-migrated with the proteins brought down by the M-and Gwspecific anti-peptide sera. None of these proteins was recognized by the MAbs in the CL fi'om mock-infected cells (Fig. 1) . When the MAbs were added to VL, two proteins were specifically immunoprecipitated which co-migrated with the 16 and 30 kDa species immunoprecipitated from the CL of EAV-infected cells by the M-and Gwspecific anti-peptide sera (Fig. 1) . The 30 kDa protein thus most likely represents the mature form of the GL protein.
It has been previously shown that the M and G L proteins of EAV are co-precipitated by antisera generated against Gw and M-specific peptide sequences, respectively (de Vries et al., 1992; unpublished results). The VP-2 or M protein from LDV is also co-precipitated by MAbs specific for the G L homologue, VP-3 (Faaberg et al., 1995) . Since the M-and GL-specific anti-peptide sera and the MAbs precipitate the same set of proteins, the MAbs recognize either the M or G L protein of EAV. To establish definitively their antigen specificity, the MAbs were used to identify EAV proteins from CL and VL by Western blotting. Western blots were performed using each of the MAbs as the primary antibody but since all exhibited the same specificity, data will be presented only for M A b 93B. As is shown in Fig. 2 methionine and then chased for up to 120 min. The G L protein was precipitated from total lysates of cells and medium using the GL-specific anti-peptide serum or MAb 93B. As is shown in Fig. 3 , the 27 kDa protein was slowly converted into the 30 k D a protein, which indicated that it is a precursor of the mature G L protein. In contrast to the situation in BHK-21 cells (de Vries et al., 1992; A. A. F. de Vries et al., unpublished results) , the maturation of the G L protein in EO cells was still not complete after a 2 h chase. This suggests that either the folding or intracellular transport of the G L protein proceeds less efficiently in EO cells than in BHK-21 cells. Moreover, although the mature G L protein synthesized in EAVinfected EO ceils was susceptible to endo-fl-galactosidase digestion and therefore contained poly-Nacetyllactosamine (data not shown), its appearance in the gel was less heterogeneous than that of the same protein produced by EAV-infected BHK-21 cells. Apparently, the maturation of the N-linked oligosaccharide side chain of the G~ protein is not as extensive in EO cells as in BHK-21 cells. Consistent with previous findings (de Vries et al., 1992) , the amount of co-precipitating M protein increased during the chase. 
The MAbs recognize non-identical epitopes
To establish the number of epitopes defined by the MAbs, NR virus escape mutants to MAbs 93B, 74D(B) and 38F were generated and designated NR93B, NR74D and NR38F, respectively. These escape mutants were then used in VN assays to determine if the sites recognized by the MAbs were related or independent. The 38F antibody in ascites fluid was able to neutralize NR93B and NR74D at low dilutions, but none of the antibodies was able to neutralize NR38F (Table 2) . None of the MAbs was able to recognize the escape mutants by IF (data not shown). These data suggest that the epitope recognized by the 38F MAb is distinguishable from, but may not be completely independent of, that recognized by the 93B and 74D(B) MAbs.
To determine the extent of heterogeneity at the antibody binding site(s) and to investigate whether the MAbs could detect consistent differences between viruses from acutely infected horses with clinical signs and viruses obtained from persistently infected stallions, they were used to compare 19 independent EAV isolates by VN. Isolates tested were obtained from semen samples, mononuclear cells or fetal tissues as indicated in Table 1 . RK-13 cells were chosen as the indicator cells because they gave more reliable end-points than the EO cells used previously. All of the isolates except DLll were neutralized to some extent by the three MAbs (Table 2) . DL11 was not neutralized by any of the antibodies and several isolates were neutralized inefficiently by all of the MAbs. Differences in the susceptibility to VN could not be used to distinguish between isolates from acutely or persistently infected horses. Additionally, all of the field isolates were recognized by the three MAbs in IF (data not shown).
¥N comparisons done using ARVAC revealed that this virus could be differentiated from EAV-NVSL. ARVAC was efficiently neutralized by MAb 38F, but was not neutralized by MAb 74D(B) and was poorly neutralized by MAb 93B. This further supports the hypothesis that MAb 38F recognizes an epitope which is different from that recognized by the other two MAbs. The slight difference in the ability of the 93B and 74D(B) MAbs to neutralize ARVAC suggests that they interact with the G L protein in slightly different ways and are therefore not completely identical in their binding specificity.
Comparative sequence analysis of the ORF 5 genes from NR and neutralization-sensitive (NS) viruses
Differences in susceptibility to VN with MAbs are the first indication of specific heterogeneity in a viral structural protein that can be correlated with a functional attribute. To determine if differences in susceptibility to VN could be correlated with amino acid (aa) sequence differences within GL, virion RNA from both NR and NS viruses was amplified over the ORF 5 coding region by RT-PCR, sequenced and compared with the previously published sequence of EAV-Utr (den Boon et al., 1991) . Sequences were obtained for the three MAb NR viruses derived from the EAV-NVSL isolate as well as an independent NR field isolate (DLll) and ARVAC. These sequences were compared to sequences from plaque-purified EAV-NVSL virus and an independent NS field isolate (DLS).
The nucleotide (nt) sequences of the ORF 5 genes are shown in Fig. 4 ; the deduced aa sequences are illustrated in Fig. 5 . The major sequence differences occurred within the part of the ORF 5 gene encoding the second half of the G L ectodomain between nt 11300 and 11492. Within this region, all of the NR viruses had sequence differences that were not present in the NS viruses at nt 11441 (NR93B and NR74D), 11441 and 11442 (NR38F and DLll) or 11444 (ARVAC) (Fig. 4) . These nt changes resulted in an aa change of tyrosine to isoleucine (DL11), proline (NR38F) or histidine (NR93B and NR74D) at position 99 (Fig. 5) . The nt change at position 11444 in the vaccine virus sequence led to an aa change of serine to glycine at position 100.
The NR93B and NR74D viruses each possessed one additional unique aa change in the predicted G L ectodomain at position 96 (histidine to leucine) and 113 (glycine to aspartic acid), respectively. It is possible that these alterations are also involved with the NR phenotype of these escape mutants. The aa change at position 175 (isoleucine to valine) between NR74D and EAV-NVSL and at position 83 (alanine to threonine) between EAV-NVSL and NR93B and NR74D probably do not contribute to the NR phenotype of the MAb escape Fig. 4 . Comparison of the nt sequences of ORF 5 from EAV-NVSL and MAb NR escape mutants with that of NS (DLS) and NR (DL11) field isolates, ARVAC and EAV-Utr (den Boon et al., 1991) . Identity with EAV-Utr (EMBL accession number X53459) which served as the consensus sequence is indicated by a dash. Nucleotide substitutions which contribute to aa changes are marked with an asterisk. Deleted nucleotides are signified with (A). The three ambiguous nucleotides in the ARVAC sequence are indicated by the appropriate letter designation (W is A or T; Y is C or T). Triplets encoding the putative transmembrane domain of G L are underlined. The region within the DL11 sequence containing an out-of-frame deletion of 3 nt as well as three base substitutions which result in the deletion of a downstream aa is double-underlined. The insertion in the DL8 sequence between nt 30 and 31 is indicated below the DL8 sequence. et al., 1991) . Amino acid differences with EAV-Utr are shown in bold above its consensus sequence. Deleted amino acids are signified with (^). Amino acid differences which resulted from ambiguous nt designations in the vaccine virus are noted in small case letters. N-glycosylation sites are double-underlined, while the putative transmembrane domain of G L is single-underlined. Additional aa encoded at the N terminus of the DL8 sequence between aa residue 10 and 11 are under that sequence.
mutants since the NS DL8 sequence contained identical substitutions at these positions. In the other NR viruses additional unique aa changes were present at positions 54 (leucine to serine), 61 (lysine to glutamine), 69 (leucine to alanine) and 79 (aspartic acid to asparagine) for DL11 and at positions 72 (glutamine to lysine) and 104 (aspartic acid to glycine) for ARVAC, which could also interfere with VN by the MAbs.
Comparison of the sequence from EAV-Utr with that of EAV-NVSL revealed a number of changes. These include a 6 bp deletion from NT 11301 through 11306 that was present in all of the viruses derived from our Bucyrus stock. This deletion resulted in a threonine to methionine change at position 52 of the aa sequence and a two aa deletion (Fig. 5) . Overall, the sequence of our isolate of Bucyrus has a 99 % nucleotide identity with the previously published sequence, not including the 6 bp deletion. An unexpected finding was that the vaccine virus, with its extensive history of passage in cell culture, had relatively few sequence changes in comparison to EAV-Utr. In addition, even though non-plaque-purified vaccine virus RNA was amplified by RT-PCR, there were only three sites, at positions 11363, 11454 and 11819, where a majority nucleotide could not be assigned.
In all three cases, there was a double band at these positions which represented the wild-type sequence plus an additional nt.
The DL8 and DLll isolates are more divergent, sharing 93.1% and 96.2 % nt identity, respectively, with EAV-Utr. Neither of these viruses was plaque-purified prior to RT-PCR amplification, however no sequence ambiguities were detected during sequence analysis. The DL11 sequence had a 3 bp deletion at NT position 11349 through 11351, while the DL8 sequence contained a 9 bp insertion at the N terminus of the G L protein between NT 11177 and NT 11178. The deletion in the DLll sequence created a UUU codon in place ofa UUC codon which maintains a phenylalanine at aa position 68. Downstream sequence changes of a G to T at nt 11353 would have led to the creation of a UGA stop codon without the compensatory A to C change at nt 11355, leading to an aa change of leucine to alanine at position 69. An additional nt change at position 11359 led to the conservation of an aspartic acid at aa 70, sacrificing the glutamic acid at position 71.
Comparison of the distribution of nt and aa sequence changes in all of the sequences revealed a high degree of sequence conservation within the first half of the hydrophilic N-terminal domain, the predicted transmembrane domain and the C-terminal hydrophilic domain. Of the five nt changes present within the first half of the N-terminal domain, two were silent third base substitutions and one resulted in a conservative alanine to valine change. Within the hydrophobic domain, eight out of 17 nt changes did not result in aa changes and the aa changes that were present were conservative in nature. There were 21 nt changes within the C-terminal hydrophilic domain, 17 of which were silent. Of the three aa changes present within this domain two were conservative. The only non-conservative aa change present within the C-terminal domain was that of glycine to glutamic acid at position 214 in the vaccine virus.
EA V fieM isolates DL8 and D L l l contain two function N-glycosylation sites
Examination of the predicted ORF 5 aa sequence from the DL8 and D L l l viruses revealed the presence of an additional potential N-glycosylation site (Fig. 5) . To determine if this site was functional, MAb 93B was used to precipitate the G L protein from [35S]methioninelabelled lysates of EO cells that were infected with DL8 or DL11. Immunoprecipitation of the G L protein from the DL11 virus was possible because, although the virus was not neutralized by any of the MAbs, the ability of the MAbs to recognize this virus by IF (data not shown) indicated that the antibodies could still bind to the polypeptide. Results demonstrated that the second Nglycosylation site is used in both isolates (Fig. 6, lanes 2  and 3) . The mature G~ protein from the DL8 and DL11 isolates was approximately 8 kDa larger than the G L protein from EAV-NVSL, with an appropriate upward shift in the glycosylated G L precursor.
D i s c u s s i o n
We report the identification and characterization of three MAbs which neutralize the infectivity of EAV. Each of the MAbs, 93B, 74D(B) and 38F, recognizes the 30 kDa major glycoprotein (G 0 of the virus. The difference in the size and appearance between the G L protein derived from EAV-NVSL-infected EO cells and that produced by BHK-21 cells infected with EAV-Utr (de Vries et al., 1992) may be due to the aa sequence changes and the two aa deletion present in the NVSL isolate, as well as to cell type-specific differences in glycosylation. The heterogeneous appearance of the mature GL protein was due entirely to maturation of its N-linked carbohydrate as digestion with N-glycosidase F converted both the 27 kDa and 30 kDa forms to a single discrete band of approximately 25 kDa (A. Glaser, unpublished results). Differences in the appearance of the mature G L protein produced in different cell lines have been reported previously (de Vries et al., 1993) . Similar cell type-specific differences in electrophoretic migration have been observed for the NB protein of influenza B virus, which is also modified with poly-N-acetyllactosamine (Williams & Lamb, 1988) .
The development of neutralizing MAbs which recognize the G L protein of EAV has allowed the functional comparison of this protein among several EAV isolates. The susceptibility of 18 out of 19 independent field isolates of EAV to neutralization by the MAbs is consistent with previous data which suggests that differences between EAV isolates are subtle (Fukunaga & McCollum, 1977) . With the exception of ARVAC, the titre at which the isolates were neutralized by all three MAbs was generally consistent. Since the MAbs recognized all of the field isolates, including D L l l , by IF in acetone-fixed cells, differences in binding affinity may contribute to differences in VN titres. While differences in the clinical presentation of acute infection suggest that there may be variation between virus isolates McCollum & Swerczek, 1978) , there is no apparent correlation between the susceptibility to VN with the MAbs and the origin of the virus isolates. Isolates obtained from semen of persistently infected stallions could not be differentiated from EAV-NVSL or other isolates obtained from clinically affected horses. The differences in the susceptibility to VN with the MAbs distinguish ARVAC from EAV-NVSL but at present there are insufficient data to associate this difference with the attenuated phenotype of the vaccine virus.
Only one variable region, located within the second half of the N-terminal hydrophilic domain, extending from aa 51 to 104, was identified. Resistance to VN is associated with aa substitutions at position 99 or 100 within this variable region. The sequence changes in the different NR viruses suggest that tyrosine at position 99 is critical for the ability of all the MAbs to neutralize virus, changes at position 100 or higher (ARVAC) affect only MAbs 93B and 74D(B). A number of antigenic sites are predicted within this region using the algorithm of Jameson & Wolf (1988) , but none of the predicted sites correlates with sequences around position 99 (data not shown). It is possible that the aa sequences around positions 99 and 100 are not directly involved in antibody binding. Sequence changes in this region may affect secondary structure and prevent antibody access to adjacent regions. It is also possible that non-unique changes in combination with unique changes may cumulatively result in a NR phenotype. Peptide binding studies will be needed to characterize further the epitope specificities of these antibodies.
The position and character of the nt and deduced aa sequence differences between EAV isolates within ORF 5 suggest that the protein has a highly conserved structure. Of the 46 sites where nt substitutions occur outside of the variable region between nt 11300 and 11458, 29 or 63 % are silent and 22% result in similar side chain aa substitutions. This strongly implies that non-conservative aa substitutions within these regions are poorly tolerated.
The presence of an additional functional Nglycosylation site in the ORF 5 aa sequence of both DL8 and DLll suggests that the single site present in the Bucyrus ORF 5 protein may not be representative of other EAV isolates. The presence of a second carbohydrate side chain does not interfere with VN by the MAbs because the DL8 isolate, which contains an additional N-glycosylation site at the same position as the NR DL11 isolate, is effectively neutralized.
Evidence from several different investigations suggests that the G L protein is the major target for neutralizing antibodies. Two other groups have identified EAVspecific neutralizing MAbs (Balasuriya et al., 1993; Deregt et al., 1994) . All of the antibodies react with the G L protein (Deregt et al., 1994; Balasuriya et al., 1995) and define a neutralization site which the antibodies recognize in interactive, overlapping epitopes. Mutations within the region between aa 95 and 104 have been defined in NR viruses obtained after selection with the neutralizing MAbs of Balasuryia et al. (1993) (Balasuriya et al., 1995) . Binding of VN ÷ convalescent equine sera to bacterial fusion proteins derived from ORF 5 have also confirmed that the G L protein is a major target during natural infection and horses immunized with a peptide sequence encompassing aa residues 75 through 97 develop neutralizing antibodies (Chirnside et al., 1995) . Taken together, these data suggest that a dominant neutralizing domain between aa residues 75 and 104 has been identified within the G L protein. However, it is likely that other regions of the G r protein may be involved in VN as the serum from an experimentally infected horse was still able to neutralize the MAb NR viruses generated by Balasuriya et al. (1995) . The sequence information presented here suggest that most variation in G L between isolates occurs within this domain. The range of variation present among isolates and the significance of this variation in disease pathogenesis, diagnosis and vaccine development remains to be determined.
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